...
首页> 外文期刊>OncoTargets and therapy >Construction of a specific SVM classifier and identification of molecular markers for lung adenocarcinoma based on lncRNA-miRNA-mRNA network
【24h】

Construction of a specific SVM classifier and identification of molecular markers for lung adenocarcinoma based on lncRNA-miRNA-mRNA network

机译:基于lncRNA-miRNA-mRNA网络的肺腺癌特异性SVM分类器的构建及分子标记物的鉴定

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Novel diagnostic predictors and drug targets are needed for LUAD (lung adenocarcinoma). We aimed to build a specific SVM (support vector machine) classifier for diagnosis of LUAD and identify molecular markers with prognostic value for LUAD. Methods: The expression differences of miRNAs, lncRNAs and mRNAs between LUAD and normal samples were compared using data from TCGA (The Cancer Genome Atlas) database. A LUAD related miRNA-lncRNA-mRNA network was constructed, based on which feature genes were selected for the construction of LUAD specific SVM classifier. The robustness and transferability of SVM classifier were validated using gene expression profile datasets GSE43458 and GSE10072. Prognostic markers were identified from the network. A set of LUAD-related differentially expressed miRNAs, lncRNAs and miRNAs were identified and a LUAD related miRNA-lncRNA-mRNA network was obtained. The LUAD specific SVM classifier constructed on the basis of the network was robust and efficient for classification of samples from TCGA dataset and two independent validation datasets. Results: Eight RNAs with prognostic value were identified, including hsa-miR-96, hsa-miR-204, PGM5P2 (phosphoglucomutase 5 pseudogene 2), SFTA1P (surfactant associated 1), RGS20 (regulator of G protein signaling 20), RGS9BP (RGS9-binding protein), FGB (fibrinogen beta chain) and INA (alpha-internexin). Among them, RGS20 and INA were regulated by hsa-miR-96. RGS20 was also regulated by hsa-miR-204, which was a potential target of SFTA1P. Conclusion: The LUAD specific SVM classifier may serve as a novel diagnostic predictor. hsa-miR-96, hsa-miR-204, PGM5P2, SFTA1P, RGS20 , RGS9BP , FGB and INA may serve as prognostic markers in clinical practice.
机译:背景:LUAD(肺腺癌)需要新的诊断预测因子和药物靶标。我们的目标是建立用于诊断LUAD的特定SVM(支持向量机)分类器,并鉴定具有LUAD预后价值的分子标记。方法:使用TCGA(癌症基因组图谱)数据库中的数据,比较LUAD和正常样品之间miRNA,lncRNA和mRNA的表达差异。构建了与LUAD相关的miRNA-lncRNA-mRNA网络,在此基础上选择了特征基因以构建LUAD特异性SVM分类器。使用基因表达谱数据集GSE43458和GSE10072验证了SVM分类器的鲁棒性和可移植性。从网络中识别出预后指标。鉴定出一组LUAD相关的差异表达miRNA,lncRNA和miRNA,并获得了LUAD相关的miRNA-lncRNA-mRNA网络。基于网络构建的LUAD特定SVM分类器对于来自TCGA数据集和两个独立的验证数据集的样本分类是强大而有效的。结果:鉴定了八个具有预后价值的RNA,包括hsa-miR-96,hsa-miR-204,PGM5P2(磷酸葡萄糖突变酶5假基因2),SFTA1P(表面活性剂相关1),RGS20(G蛋白信号调节剂20),RGS9BP( RGS9结合蛋白),FGB(纤维蛋白原β链)和INA(α-internexin)。其中,RGS20和INA受hsa-miR-96调控。 RGS20也受hsa-miR-204调控,后者是SFTA1P的潜在靶标。结论:LUAD特定的SVM分类器可以作为一种新颖的诊断预测指标。 hsa-miR-96,hsa-miR-204,PGM5P2,SFTA1P,RGS20,RGS9BP,FGB和INA可作为临床实践中的预后标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号